

CONSENT AWARD

dated 3 May 2024 and issued by the

FEI TRIBUNAL

Sitting in the following composition:

Sole Panel Member: Mr Brian Ward (CAN)

in the matter between:

FÉDÉRATION EQUESTRE INTERNATIONALE (FEI)

and

Abdulaziz ALKHADEM in his capacity as the **Additional Person Responsible** in the following case:

Case: C24-0013 ALKHADEM

FEI Case reference: 2024/FT11 [REDACTED]

Person Responsible/ID/NF [REDACTED]

Trainer/ID/NF: Abdulaziz ALKHADEM/10074082/KSA

Horse/ID/NF: [REDACTED]

Event/Date/ID: CEI1*100 - Al Ula (KSA), 23-24.02.2024, 2024_CI_0279_E_S_03

Date of sample collection: 24.02.2024

Prohibited Substance(s): Phenylbutazone, Oxyphenbutazone

Bar Code Number: 5637254

All the words used in this Consent Award beginning with a capital letter and not previously defined have the meaning set forth in the specific definitions of the FEI General Regulations and Statutes, the FEI Endurance Rules, the 2022 Equine Prohibited Substance List and the Equine Anti-Doping and Controlled Medication Regulations (the **EADCMRs**). The Equine Anti-Doping Rules (the **EAD Rules**) and the Equine Controlled Medication Rules (the **ECM Rules**) are set out in the EADCMRs.

I. Parties

1. The Fédération Equestre Internationale (the **FEI**) is the sole IOC recognised International Federation for equestrian sport. The FEI is the governing body for the FEI equestrian disciplines of dressage, jumping, eventing, driving, endurance, vaulting, and para-equestrian.
2. Mr Abdulaziz ALKHADEM (FEI ID 10074082), the Additional Person Responsible (the **APR**), is a Trainer from Saudi Arabia, and was the registered Trainer for the horse, [REDACTED] (the **Horse**), which competed at the CEI1* 100 in Al Ula (KSA), on 23-24 February 2024 (the **Event**).

II. Factual background and initial proceedings

3. The Horse was tested during the Event and returned a positive result for Phenylbutazone, and Oxyphenbutazone. Phenylbutazone is a non-steroidal anti-inflammatory medication used to relieve pain, inflammation and to control fever. Oxyphenbutazone is a metabolite of Phenylbutazone. Both substances are classified as a Controlled Medication Substances under the FEI Equine Prohibited Substances List.
4. The FEI informed the APR of the positive result in a notification letter dated 25 March 2024 (the **Notification Letter**).
5. In accordance with Article 7.4.1 of the ECM Rules, the APR was not provisionally suspended.
6. In the Notification Letter, the FEI provided the APR with the opportunity to admit the violation, accept the sanctions and receive an automatic three (3) months reduction in the Period of Ineligibility.
7. On 30 March 2024, the APR admitted the ECM Rule violation and submitted a duly signed Acceptance of Consequences Form to the FEI.

III. Summary of the proceeding before the FEI Tribunal

8. On 9 April 2024, the FEI submitted the duly signed Acceptance of Consequences Form together with the Notification Letter to the FEI Tribunal, and requested that the FEI Tribunal issue this Consent Award, confirming the accepted consequences that would be imposed on the APR.
9. On 23 April 2024, the Tribunal informed the Parties of the appointment of a one-person hearing panel to adjudicate and approve this matter. The Parties were asked to provide any objections to the constitution of the hearing panel by 26 April 2024.
10. On 23 April 2024, the FEI informed the Tribunal that it did not have any objections to the constitution of the hearing panel.
11. Within the prescribed deadline, the APR did not provide any objection to the nomination of the hearing panel.
12. Neither party requested an oral hearing.

IV. Jurisdiction

13. The jurisdiction of the FEI Tribunal, which is not disputed, derives from the:

Statutes 24th edition, effective 17 November 2021 ("Statutes"), Articles 1.5, 38 and 39.

General Regulations, 24th edition, updates effective 1 January 2024, Articles 118, 143.1, 159, 164, 165 and 167 ("GRs").

Internal Regulations of the FEI Tribunal, 3rd Edition, 2 March 2018 ("IRs").

FEI Equine Anti-Doping and Controlled Medication Regulations ("EADCMRs"), 3rd edition, effective 1 January 2021, updates effective 1 January 2023.

V. Early Admission and Acceptance of Sanction

14. In accordance with Article 10.8.1 of the ECM Rules: *"Where Person Responsible and/or member of the Support Personnel and/or other Person, after being notified by the FEI of a potential ECM Rule violation that carries an asserted period of Ineligibility of six (6) months or more (including any period of Ineligibility asserted under Article 10.4), admits the violation and*

accepts the asserted period of Ineligibility no later than twenty (20) days after receiving notice of an ECM Rule violation charge, the Person Responsible and/or member of the Support Personnel and/or other Person may receive a three (3) month reduction in the period of Ineligibility asserted by the FEI. Where the Person Responsible and/or member of the Support Personnel and/or other Person receives the three (3) month reduction in the asserted period of Ineligibility under this Article 10.8.1, no further reduction in the asserted period of Ineligibility shall be allowed under any other Article.”

VI. Ratification of the Accepted Consequences

15. The APR has explicitly admitted the ECM Rule violation and accepted the following consequences (in accordance with the Article 10.8.1 of the ECM Rules):
 - o a period of Ineligibility of three (3) months commencing from the date of the Final Decision by the FEI Tribunal; and
 - o a fine of CHF 2'500.
16. The sole panel member confirms that the above Accepted Consequences comply with the ECM Rules and finds no grounds to object to their terms.

ON THESE GROUNDS

1. The sole panel member hereby ratifies the Accepted Consequences in the case of C24-0013 ALKHADEM [2024/FT11 - ██████████] and incorporates its terms into this Consent Award.
2. Each Party is hereby ordered to perform the obligations and duties pursuant to the Accepted Consequences.
3. The Consent Award is pronounced without costs.
4. This Consent Award is final and not subject to an appeal as the APR has waived this right.
5. This Consent Award will be published in accordance with Article 14.3 of the ECM Rules.

DECISION TO BE FORWARDED TO:


a. The Parties:

- FEI
- Mr Abdulaziz ALKHADEM (APR)

b. Any other:

- The NF of the APR, the KSA Equestrian Federation

FOR THE TRIBUNAL



Mr Brian Ward (CAN)